The engineering of living cells and microbes is ushering in a new era of cancer therapy. Due to recent microbiome studies indicating the prevalence of bacteria within the human body and specifically in tumor tissue, bacteria have generated significant interest as potential targets for cancer therapy. Notably, a multitude of empirical studies over the past decades have demonstrated that administered bacteria home and grow in tumors due to reduced immune surveillance of tumor necrotic cores. Given their specificity for tumors, bacteria present a unique opportunity to be engineered as intelligent delivery vehicles for cancer therapy with synthetic biology techniques. In this review, we discuss the history, current state, and future challenges associated with using bacteria as a cancer therapy.
Research Article| October 11 2019
Engineering bacteria for cancer therapy
1Department of Biomedical Engineering, Columbia University, New York, NY, U.S.A.
2Data Science Institute, Columbia University, New York, NY, U.S.A.
3Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, U.S.A.
Correspondence: Tal Danino (firstname.lastname@example.org)
Search for other works by this author on:
Emerg Top Life Sci (2019) 3 (5): 623-629.
- Views Icon Views
- Share Icon Share
- Cite Icon Cite
Tetsuhiro Harimoto, Tal Danino; Engineering bacteria for cancer therapy. Emerg Top Life Sci 11 November 2019; 3 (5): 623–629. doi: https://doi.org/10.1042/ETLS20190096
Download citation file: